The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Medtronic says real-world data show its MiniMed 670G glucose management system increased time in range for people with diabetes. Medtronic has announced clinical outcomes for the MiniMed 670G system, ...

Medtronic plc.'s MDT Diabetes Management segment is dominating the headlines of late. Following the company’s receipt of the CE Mark approval for its advanced continuous glucose monitoring (CGM) ...

Medtronic plcMDT recently announced FDA approval for its MiniMed 670G system for patients with type 1 diabetes between seven and 13 years of age. Notably, the approval was based on positive data from ...

Children with Type 1 diabetes will now have access to the Medtronic MiniMed 670G, a hybrid closed-loop system insulin delivery system, following the FDA’s decision to expand the product approval for a ...

Aggregated real-world outcome data collected from thousands of Medtronic MiniMed 670G users indicate that patients on the system spend an average 71% of their time within an optimal glycemic range.

Medtronic's next-generation automated insulin delivery system offers significant improvements over the currently available 670G hybrid closed-loop, particularly in young people with type 1 diabetes, ...

In a recent press release, Medtronic announced that is has received CE (Conformité Européenne) Mark for the MiniMed(TM) 670G hybrid closed loop system – the first and only system to automate and ...